AlzeCure receives approval to start clinical Phase Ib trial with ACD440 in neuropathic pain
See the latest presentation with CEO Martin Jönsson when he is interviewed by Aktiespararnas Analysguiden.
Alzecure is highlighted in a report on research on Alzheimer’s and neurodegenerative diseases
AlzeCure Pharma is a Swedish pharmaceutical company focusing on the research and development of innovative and efficacious treatments for Alzheimer’s disease and related disorders
AlzeCure is developing disease modifying and symptomatic first in class treatments for Alzheimer’s disease and other conditions characterized by cognitive dysfunction
Alzheimer’s disease is a deadly disorder which lacks effective treatments. The need for novel treatments is therefore urgent.